May 8 |
When Can We Expect A Profit From Coherus BioSciences, Inc. (NASDAQ:CHRS)?
|
May 8 |
Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer
|
May 1 |
Coherus to Report First Quarter 2024 Financial Results on May 9, 2024
|
Apr 24 |
Coherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
|
Apr 11 |
Investors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five years
|
Apr 8 |
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
|
Mar 21 |
Coherus Biosciences: Dumping One Drug But Showing Promise With Another
|
Mar 16 |
Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call Transcript
|
Mar 15 |
Coherus BioSciences Full Year 2023 Earnings: EPS Misses Expectations
|
Mar 14 |
Why Coherus Biosciences Stock Tumbled on Thursday
|